The role of glucocorticoids in inflammatory diseases
SD Reichardt, A Amouret, C Muzzi, S Vettorazzi… - Cells, 2021 - mdpi.com
For more than 70 years, glucocorticoids (GCs) have been a powerful and affordable
treatment option for inflammatory diseases. However, their benefits do not come without a …
treatment option for inflammatory diseases. However, their benefits do not come without a …
Glucocorticoids and COVID-19
S Bruscoli, PG Puzzovio, M Zaimi, K Tiligada… - Pharmacological …, 2022 - Elsevier
Abstract Coronavirus Disease 19 (COVID-19) is associated with high morbidity and mortality
rates globally, representing the greatest health and economic challenge today. Several …
rates globally, representing the greatest health and economic challenge today. Several …
Discriminative accuracy of the CAPTURE tool for identifying chronic obstructive pulmonary disease in US primary care settings
Importance Chronic obstructive pulmonary disease (COPD) is underdiagnosed in primary
care. Objective To evaluate the operating characteristics of the CAPTURE (COPD …
care. Objective To evaluate the operating characteristics of the CAPTURE (COPD …
Update on asthma–COPD overlap (ACO): a narrative review
E Mekov, A Nuñez, DD Sin, M Ichinose… - … Journal of Chronic …, 2021 - Taylor & Francis
Although chronic obstructive pulmonary disease (COPD) and asthma are well-characterized
diseases, they can coexist in a given patient. The term asthma–COPD overlap (ACO) was …
diseases, they can coexist in a given patient. The term asthma–COPD overlap (ACO) was …
Epidemiology, healthcare resource utilization, and mortality of asthma and COPD in COVID-19: a systematic literature review and meta-analyses
DMG Halpin, AP Rabe, WJ Loke, S Grieve… - Journal of asthma …, 2022 - Taylor & Francis
Purpose There has been concern that asthma and chronic obstructive pulmonary disease
[COPD] increase the risk of developing and exacerbating COVID-19. The effect of …
[COPD] increase the risk of developing and exacerbating COVID-19. The effect of …
Emerging applications and prospects of NFκB decoy oligodeoxynucleotides in managing respiratory diseases
Chronic respiratory diseases like asthma and Chronic Obstructive Pulmonary Disease
(COPD) have been a burden to society for an extended period. Currently, there are only …
(COPD) have been a burden to society for an extended period. Currently, there are only …
Reversible airflow obstruction predicts future chronic obstructive pulmonary disease development in the SPIROMICS cohort: an observational cohort study
RG Buhr, IZ Barjaktarevic, PM Quibrera… - American journal of …, 2022 - atsjournals.org
Rationale: Chronic obstructive pulmonary disease (COPD) is defined by fixed spirometric
ratio, FEV1/FVC< 0.70 after inhaled bronchodilators. However, the implications of variable …
ratio, FEV1/FVC< 0.70 after inhaled bronchodilators. However, the implications of variable …
The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS)
TE Albertson, JA Chenoweth, SJ Pearson… - Expert opinion on …, 2020 - Taylor & Francis
Introduction: Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) is a
disease phenotype that shares T helper lymphocyte cell Th1/neutrophilic/non-Type-2 …
disease phenotype that shares T helper lymphocyte cell Th1/neutrophilic/non-Type-2 …
Effects of a Peptide Derived from the Primary Sequence of a Kallikrein Inhibitor Isolated from Bauhinia bauhinioides (pep-BbKI) in an Asthma–COPD Overlap (ACO) …
LLS Silva, JAS Barbosa, JMLG João… - International Journal of …, 2023 - mdpi.com
(1) There are several patients with asthma–COPD overlap (ACO). A peptide derived from the
primary sequence of a kallikrein inhibitor isolated from Bauhinia bauhinioides (pep-BbKI) …
primary sequence of a kallikrein inhibitor isolated from Bauhinia bauhinioides (pep-BbKI) …
Phosphodiesterase-4 inhibitors for non-COPD respiratory diseases
T Kawamatawong - Frontiers in pharmacology, 2021 - frontiersin.org
Selective phosphodiesterase (PDE) inhibitors are a class of nonsteroid anti-inflammatory
drugs for treating chronic inflammatory diseases. Modulation of systemic and airway …
drugs for treating chronic inflammatory diseases. Modulation of systemic and airway …